SLC2A1 and brain neoplasm: By incorporating maltobionic acid (a GLUT1-recognized glucose derivative) and 4-carboxyphenylboronic acid, this system improved drug stability, facilitated BBB transport, and significantly inhibited tumor growth in preclinical models of aggressive brain tumors [66,67].